A biomarker study to evaluate circulating tumor cell count (CTC) and expression of pERK and pAKT in CTCs as biomarkers for sorafenib efficacy in patients with advanced hepatocellular carcinoma

Trial Profile

A biomarker study to evaluate circulating tumor cell count (CTC) and expression of pERK and pAKT in CTCs as biomarkers for sorafenib efficacy in patients with advanced hepatocellular carcinoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Dec 2015

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 26 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top